Physical activity support for prostate cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to improve physical activity levels among prostate cancer patients by implementing a personalized intervention program that combines support from health professionals and peers. The program encourages patients to engage in at least 150 minutes of brisk walking per week, which is linked to reduced cancer mortality and recurrence. By utilizing physical activity support devices and personalized coaching, the study seeks to initiate and sustain regular physical activity over the long term. The intervention targets patients who are currently insufficiently active and have been diagnosed with prostate cancer for at least one year.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients:

* Age ≥ 18 years
* Diagnosed with prostate cancer for at least 1 year
* PA practice \< 150 minutes per week (considered inactive according to WHO)
* Affiliated or entitled to a social security scheme
* Having received informed information about the study and having co-signed, with the investigator, a consent to participate in the study

Exclusion Criteria:

For patients:

* Undergoing treatment (except hormone therapy)
* Significant comorbidities contraindicating the practice of physical activity: associated cardiac pathologies, respiratory pathologies, disabling joint pathologies
* Deprived of liberty or under guardianship

Where it's running

• CHU Saint-Etienne - Oncologie
  Saint-Etienne, France Recruiting
• Hôpital Privé de la Loire
  Saint-Etienne, France Recruiting
• Activité Physique Adaptée - CDOS Savoie
  Chambéry, France Not yet recruiting
• CH Chambéry
  Chambéry, France Not yet recruiting
• Activité Physique Adaptée - DAHLIR 63
  Clermont-Ferrand, France Not yet recruiting
• CHU Clermont-Ferrand - ONCOLOGIE
  Clermont-Ferrand, France Not yet recruiting

Study contacts

• Principal investigator: David HUPIN, MD PhD — CHU de Saint-Etienne
• Study coordinator: Hupin David, Md
• Email: David.Hupin@chu-st-etienne.fr
• Phone: (0)477828413

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.